JP2005530787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530787A5 JP2005530787A5 JP2004505057A JP2004505057A JP2005530787A5 JP 2005530787 A5 JP2005530787 A5 JP 2005530787A5 JP 2004505057 A JP2004505057 A JP 2004505057A JP 2004505057 A JP2004505057 A JP 2004505057A JP 2005530787 A5 JP2005530787 A5 JP 2005530787A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- core
- composition according
- lactose
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- 229920002261 Corn starch Polymers 0.000 claims 3
- 239000008120 corn starch Substances 0.000 claims 3
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims 3
- 229960002053 flibanserin Drugs 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- PUQZBGPEFQZKIG-UHFFFAOYSA-N 2-methylidenebutanoic acid;methyl 2-methylprop-2-enoate Chemical compound CCC(=C)C(O)=O.COC(=O)C(C)=C PUQZBGPEFQZKIG-UHFFFAOYSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 150000002597 lactoses Chemical class 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 239000006082 mold release agent Substances 0.000 claims 1
- 229920000120 polyethyl acrylate Polymers 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02011224 | 2002-05-22 | ||
| PCT/EP2003/005226 WO2003097058A1 (en) | 2002-05-22 | 2003-05-19 | New pharmaceutical compositions containing flibanserin polymorph a |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005530787A JP2005530787A (ja) | 2005-10-13 |
| JP2005530787A5 true JP2005530787A5 (enExample) | 2006-02-16 |
| JP3919788B2 JP3919788B2 (ja) | 2007-05-30 |
Family
ID=29433081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505057A Expired - Fee Related JP3919788B2 (ja) | 2002-05-22 | 2003-05-19 | フリバンセリン多形ａを含む新規医薬組成物 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1511489B1 (enExample) |
| JP (1) | JP3919788B2 (enExample) |
| KR (1) | KR101054237B1 (enExample) |
| CN (3) | CN102240289A (enExample) |
| AT (1) | ATE499939T1 (enExample) |
| BR (1) | BRPI0311189B8 (enExample) |
| CA (1) | CA2483597C (enExample) |
| CY (1) | CY1111470T1 (enExample) |
| DE (1) | DE60336225D1 (enExample) |
| DK (1) | DK1511489T3 (enExample) |
| EA (1) | EA007185B1 (enExample) |
| EC (1) | ECSP045493A (enExample) |
| ES (1) | ES2361994T3 (enExample) |
| HR (1) | HRP20041092B1 (enExample) |
| IL (1) | IL164440A0 (enExample) |
| ME (1) | MEP55308A (enExample) |
| MX (1) | MXPA04011487A (enExample) |
| NO (1) | NO329414B1 (enExample) |
| NZ (1) | NZ537253A (enExample) |
| PL (1) | PL211062B1 (enExample) |
| RS (1) | RS51718B (enExample) |
| SI (1) | SI1511489T1 (enExample) |
| UA (1) | UA80135C2 (enExample) |
| WO (1) | WO2003097058A1 (enExample) |
| ZA (1) | ZA200408151B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| EP1912650B8 (en) | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| JP2009541443A (ja) * | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| KR20090042967A (ko) | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
| CN104721168A (zh) | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
| WO2008074795A1 (en) | 2006-12-20 | 2008-06-26 | Boehringer Ingelheim International Gmbh | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
| EP1955699A1 (en) * | 2007-02-08 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flibanserin for the treatment of insomnia |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| EP2090297A1 (en) * | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
| CN104926734B (zh) * | 2015-07-07 | 2017-04-05 | 苏州立新制药有限公司 | 氟班色林的制备方法 |
| WO2017128932A1 (zh) * | 2016-01-31 | 2017-08-03 | 孟晓明 | 氟班色林的新晶型及其制备方法及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| AU2002331361B2 (en) * | 2001-08-02 | 2008-06-05 | Sprout Pharmaceuticals, Inc. | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
| DE10138273A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
-
2003
- 2003-05-19 RS YU98704A patent/RS51718B/sr unknown
- 2003-05-19 CN CN201110122058XA patent/CN102240289A/zh active Pending
- 2003-05-19 CN CNA038117029A patent/CN1655789A/zh active Pending
- 2003-05-19 DK DK03730069.6T patent/DK1511489T3/da active
- 2003-05-19 BR BRPI0311189A patent/BRPI0311189B8/pt not_active IP Right Cessation
- 2003-05-19 NZ NZ537253A patent/NZ537253A/en not_active IP Right Cessation
- 2003-05-19 CA CA2483597A patent/CA2483597C/en not_active Expired - Fee Related
- 2003-05-19 KR KR1020047018741A patent/KR101054237B1/ko not_active Expired - Lifetime
- 2003-05-19 MX MXPA04011487A patent/MXPA04011487A/es active IP Right Grant
- 2003-05-19 ME MEP-553/08A patent/MEP55308A/xx unknown
- 2003-05-19 UA UA20041210555A patent/UA80135C2/uk unknown
- 2003-05-19 DE DE60336225T patent/DE60336225D1/de not_active Expired - Lifetime
- 2003-05-19 AT AT03730069T patent/ATE499939T1/de active
- 2003-05-19 JP JP2004505057A patent/JP3919788B2/ja not_active Expired - Fee Related
- 2003-05-19 EA EA200401515A patent/EA007185B1/ru not_active IP Right Cessation
- 2003-05-19 ES ES03730069T patent/ES2361994T3/es not_active Expired - Lifetime
- 2003-05-19 SI SI200331994T patent/SI1511489T1/sl unknown
- 2003-05-19 PL PL372457A patent/PL211062B1/pl unknown
- 2003-05-19 HR HRP20041092AA patent/HRP20041092B1/hr not_active IP Right Cessation
- 2003-05-19 WO PCT/EP2003/005226 patent/WO2003097058A1/en not_active Ceased
- 2003-05-19 CN CNA2007100014771A patent/CN101002780A/zh active Pending
- 2003-05-19 EP EP03730069A patent/EP1511489B1/en not_active Expired - Lifetime
-
2004
- 2004-10-05 IL IL16444004A patent/IL164440A0/xx unknown
- 2004-10-08 ZA ZA200408151A patent/ZA200408151B/en unknown
- 2004-10-22 NO NO20044547A patent/NO329414B1/no not_active IP Right Cessation
- 2004-12-13 EC EC2004005493A patent/ECSP045493A/es unknown
-
2011
- 2011-05-17 CY CY20111100475T patent/CY1111470T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530787A5 (enExample) | ||
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
| JP5553452B2 (ja) | ブリバラセタムを含む医薬組成物 | |
| JP2006522006A5 (enExample) | ||
| JP2019505525A (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| WO2001095912A1 (fr) | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph | |
| JP2007091758A5 (enExample) | ||
| US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
| JP2011140508A (ja) | 安定なイマチニブ組成物 | |
| JP2006527256A5 (enExample) | ||
| JP2007503414A (ja) | 新規なロピニロール処方 | |
| CN111202731B (zh) | 联合用药应用以及一种药用组合物及其应用 | |
| US20160303077A1 (en) | Novel compositions | |
| WO2021129735A1 (zh) | 一种固体制剂及其制备方法和用途 | |
| WO2014142607A1 (ko) | 약제학적 복합제제 | |
| JP2020511419A5 (enExample) | ||
| CN101084912A (zh) | 复方盐酸氨溴索缓释片及其制备方法 | |
| JP2015503555A (ja) | ボセンタン制御放出性経口製剤 | |
| JP4871258B2 (ja) | トラセミドとマトリックス形成ポリマーとを含む持続放出型組成物（ｐｒｏｌｏｎｇｅｄ−ｒｅｌｅａｓｅ ｃｏｍｐｏｓｉｔｉｏｎ） | |
| CN104856971A (zh) | 一种脉冲双释放制剂及其制备方法与应用 | |
| JPWO2021078835A5 (enExample) | ||
| RU2410097C2 (ru) | Лекарственная форма триметазидина модифицированного высвобождения и способ ее получения (варианты) | |
| CN100551369C (zh) | 一种含有西洛他唑的缓释制剂及其制备方法 | |
| WO2012075744A1 (zh) | 含有吡唑并嘧啶酮样化合物的药物组合物 |